3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Melanoma
2
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Leukemia
1
Healthy Participants
1
Endometrial Neoplasms
1
Disease Progression
1
Chondrosarcoma
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Interventions
Radiosurgery
2
neratinib
1
lutetium Lu 177 dotatate
1
capivasertib
1
avasopasem manganese
1
Valproic Acid
1
Taxes
1
Sevoflurane
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Propofol
1
Nivolumab
1
Multiparametric Magnetic Resonance Imaging
1
Gemcitabine
1
Everolimus
1
Etoposide
1
Cystectomy
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Cisplatin
1
Carboplatin
1
Blood Specimen Collection
1
Biopsy
1
Anesthesia, Inhalation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Disease Progression
×
capivasertib
×
Clear all
NCT07281833
2026-02-27
CAPIcorn
West German Study Group
Phase 3
Recruiting
250 enrolled